* Manufacturing problems at Abbott Molecular plant
* Problems uncovered during June 2009 inspection
* Abbott says already taken steps to address problems (Adds Abbott comment, background)
WASHINGTON, Nov 17 (Reuters) - U.S. regulators have warned Abbott Laboratories Inc ABT.N about poor manufacturing standards at a molecular diagnostics plant.
The U.S. Food and Drug Administration, in an Aug. 12 letter released on Tuesday, said an inspection of the company’s Des Plaines, Illinois, facility had revealed production shortfalls, resulting in adulterated devices.
The site was inspected in June and Abbott said it had taken action since receiving the FDA letter.
“We’ve already taken a number of steps to address items outlined in the letter,” said spokesman Don Braakman. (Reporting by Ben Hirschler, editing by Gerald E. McCormick)
Our Standards: The Thomson Reuters Trust Principles.